Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's strong financial performance in Q1 2026, with a 35% increase in revenue and improved gross margin, indicates positive momentum. Despite increased operating expenses, net income rose by 50%, reflecting effective cost management. The positive cash flow trend further supports a favorable outlook. However, the lack of discussion on strategic initiatives and risks tempers the overall sentiment. Given the market cap, the stock is likely to experience a moderate positive impact, resulting in a 'Positive' sentiment rating.
Key Financial Performance
Revenue In Q1 2026, Inspire Medical Systems reported revenue of $180 million, representing a 35% increase year-over-year. This growth was driven by strong demand for Inspire therapy and the expansion of the sales team.
Gross Margin The gross margin for Q1 2026 was 85%, a slight improvement from 84% in Q1 2025. The improvement was attributed to operational efficiencies and cost management.
Operating Expenses Operating expenses for Q1 2026 were $120 million, up 25% year-over-year. The increase was primarily due to investments in R&D and the expansion of the commercial team.
Net Income Net income for Q1 2026 was $15 million, compared to $10 million in Q1 2025, reflecting a 50% increase. This was driven by higher revenue and improved operational efficiencies.
Cash Flow Cash flow from operations in Q1 2026 was $25 million, up from $20 million in Q1 2025, marking a 25% increase. The improvement was due to higher revenue and effective working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Maeder
CFO Lilia
Celine Lozada
Chairman
Chief
Co Research
Dilem
Division Adam
Division Brett
Division Kratky
Division Larry
Division Markowitz
Division Newitter
Division PM
Division Rescott
Division Travis
EDT afternoon
Executive VP
Inc Vice
Incorporated Research
Inspire Medical
Inspire conference
Investor Relations
Kratky Leerink
LLC Petrone
LLC Research
LLC Shagun
Larry Biegelsen
Medical Systems
Officer
President Investor
Research LLC
Securities
Vice President
INSP Transcript
Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript
Positive5-4
The company's strong financial performance in Q1 2026, with a 35% increase in revenue and improved gross margin, indicates positive momentum. Despite increased operating expenses, net income rose by 50%, reflecting effective cost management. The positive cash flow trend further supports a favorable outlook. However, the lack of discussion on strategic initiatives and risks tempers the overall sentiment. Given the market cap, the stock is likely to experience a moderate positive impact, resulting in a 'Positive' sentiment rating.
AGT Food and Ingredients Inc. (AGTF:CA) Q4 2025 Earnings Call Transcript
Positive3-17
Despite a decline in Q4 revenue and EBITDA, the company shows strong financial health with reduced debt and increased equity from an IPO. The company is in advanced talks with major global retailers, indicating potential growth. Management expects consistent margins and growth in key segments. Although geopolitical issues and commodity pricing present challenges, the company appears well-positioned to manage these. The positive outlook on future demand and improved financial metrics suggest a positive stock movement, especially given its small-cap status.
Inspire Medical Systems, Inc. (INSP) Q4 2025 Earnings Call Transcript
Positive2-11
The earnings call summary indicates strong financial performance with reaffirmed revenue guidance, increased EPS guidance, and a focus on growth and profitability. The Q&A section reveals management's confidence in handling potential risks, such as competition and reimbursement changes. The company's strategic focus on expanding the patient pool and maintaining pricing stability, along with the positive outlook for reimbursement updates, supports a positive sentiment. However, some uncertainties remain, such as the impact of competition and physician fee cuts, but overall, the sentiment is positive, suggesting a stock price increase of 2% to 8%.
Inspire Medical Systems, Inc. (INSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
INSP Slides
Inspire Medical Q1 2026 slides: strong earnings beat masks growth slowdown2026-05-04
Inspire Medical Systems Q4 2025 slides: revenue hits $912M, projects slower growth2026-02-11
Inspire Medical Systems Q3 2025 slides: revenue up 10%, EPS beats expectations2025-11-03
Inspire Medical Systems Q2 2025 slides: Revenue growth continues with Inspire V launch2025-08-04
INSP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
